

Clinical Trial Protocol

Iranian Registry of Clinical Trials

06 Jul 2026

Comparison of vaginal misoprostol, combination of vaginal misoprostol and letrozole and combination of misoprostol and laminaria for preoperative cervical ripening in under second trimester abortions

Protocol summary

Summary

Objectives: Comparison of the efficacy of vaginal misoprostol with and without letrozole and combination of misoprostol and laminaria for preoperative cervical ripening among women with under second trimester abortion. Design: In this interventional study, 120 pregnant women under 20 weeks of gestational age who are candidates for therapeutic abortion will be selected and divided into three groups using block randomization method (n=40 in each group). Inclusion criteria: Under 20 weeks pregnancy and fetal death. Exclusion criteria: Cesarean section history; adrenal diseases; asthma; history of thromboembolism. Proper counseling will be done and a written informed consent will be obtained before starting the treatment regimen. Setting and conduct: One group will receive vaginal misoprostol alone (produced by Pfizer Company), 600 µg every 4 hours for 5 days for women in the gestational age of 13 weeks or less and 200 µg every 4 hours for 5 days in women with the gestational age of 14 - 20 weeks and the second group will receive oral placebo and vaginal misoprostol (like the first group), also they will receive 5 mm laminaria (produced by Cytotec Company) for 6 hours as well. In the third group, oral letrozole (Iran Hormon Company), 10 mg daily in combination with cervical placebo will be prescribed on first and second day and in third day, patients will be hospitalized and receive vaginal misoprostol (like the first group) and third dose of oral letrozole. Patients will regularly be examined every 4 hours and in the absence of abortion, vaginal misoprostol will be repeated after 4 hours. Eight hours after intervention, patients will be assessed using transvaginal ultrasound and no report of products of conception (POC) will be considered as complete abortion and the patient will be discharged. Otherwise, patients will be assessed by transvaginal ultrasound again on next day. For patients who have uncompleted

expulsion of POC, curettage abortion will be done. For every patient, pain intensity on the VAS scale will be recorded.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2016100923559N6**

Registration date: **2016-12-30, 1395/10/10**

Registration timing: **prospective**

Last update:

Update count: **0**

Registration date

2016-12-30, 1395/10/10

Registrant information

Name

Somaieh Matin

Name of organization / entity

Ardabil University of Medicine Sciences

Country

Iran (Islamic Republic of)

Phone

+98 45 3373 3011

Email address

s.matin@arums.ac.ir

Recruitment status

Recruitment complete

Funding source

Vice chancellor for research, Ardabil University of Medical Sciences

Expected recruitment start date

2017-01-20, 1395/11/01

Expected recruitment end date

2017-04-21, 1396/02/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparison of vaginal misoprostol, combination of vaginal misoprostol and letrozole and combination of misoprostol and laminaria for preoperative cervical ripening in under second trimester abortions

Public title

Use of vaginal misoprostol with and without letrozole and combination of misoprostol and laminaria for preoperative cervical ripening

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: Under 20 weeks pregnancy and fetal death. Exclusion criteria: Cesarean section history; adrenal diseases; asthma; history of thromboembolism

Age

No age limit

Gender

Female

Phase

2

Groups that have been masked

No information

Sample size

Target sample size: **120**

Randomization (investigator's opinion)

N/A

Randomization description**Blinding (investigator's opinion)**

Triple blinded

Blinding description**Placebo**

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Ardabil University of Medical Sciences

Street address

Ardabil University of Medicine Sciences, Daneshgah street, Ardabil

City

Ardabil

Postal code

53141-56198

Approval date

2016-10-30, 1395/08/09

Ethics committee reference number

IR.ARUMS.REC.1395.55

Health conditions studied**1****Description of health condition studied**

Medical abortion

ICD-10 code

000-008

ICD-10 code description

Medical abortion

Primary outcomes**1****Description**

Fetus abortion

Timepoint

Eight hours after the intervention, and every twenty-four hours up to three days if the abortion doesn't occur

Method of measurement

Transvaginal Ultrasonography

Secondary outcomes**1****Description**

Pain

Timepoint

Every four hours until abortion occurs and at the time that abortion occurs

Method of measurement

Visual analog scale

Intervention groups**1****Description**

Intervention group 1: Vaginal misoprostol, produced by Pfizer Company, 600 µg every 4 hours for 5 days in women with the gestational age of 13 weeks or less and 200 µg every 4 hours for 5 days in women with the gestational age of 14 -20 weeks

Category

Treatment - Drugs

2**Description**

Intervention group 2: Oral letrozole, produced by Iran Hormon Company, 10 mg daily and vaginal misoprostol, produced by Pfizer Company, 600 µg every 4 hours for 5

days for women in the gestational age of 13 weeks or less and 200 µg every 4 hours for 5 days in women with the gestational age of 14 - 20 weeks.

Category

Treatment - Drugs

3**Description**

Intervention group 3: vaginal laminaria, produced by Cytotec Company, 5mm for 6 hours and vaginal misoprostol, produced by Pfizer Company, 600 µg every 4 hours for 5 days for women in the gestational age of 13 weeks or less and 200 µg every 4 hours for 5 days in women with the gestational age of 14 - 20 weeks.

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Alavi Hospital

Full name of responsible person

Dr. Mahsa Valaee

Street address

Alavi Hospital, Moadi street, Ardabil

City

Ardabil

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Vice chancellor for research, Ardabil University of Medical Sciences

Full name of responsible person

Dr Shahram Habibzadeh

Street address

Ardabil University of Medical Science, Daneshgah street, Ardabil, Iran

City

Ardabil

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Vice chancellor for research, Ardabil University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

empty

Person responsible for general inquiries**Contact****Name of organization / entity**

Ardabil University of Medical Sciences

Full name of responsible person

Dr. Mahsa Valaee

Position

Gynecology Asisstant

Other areas of specialty/work**Street address**

Alavi Hospital, Moadi street, Ardabil

City

Ardabil

Postal code**Phone**

+98 45 3324 8888

Fax**Email**

mshpartovi@gmail.com

Web page address**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Ardabil University of Medical Sciences

Full name of responsible person

Dr. Fariba Kahnamoee Agdam

Position

gynecologist, Gynecology Department

Other areas of specialty/work**Street address**

Alavi Hospital, Moadi street, Ardabil

City

Ardabil

Postal code

5615783134

Phone

+98 45 3324 8888

Fax**Email**

f.kahnamuee.a@arums.ac.ir

Web page address**Person responsible for updating data****Contact****Name of organization / entity**

Ardabil University of Medical Sciences

Full name of responsible person

Dr. Mahsa Valaee

Position

Gynecology Asisstant

Other areas of specialty/work**Street address**

Alavi Hospital, Moadi street, Ardabil

City

Ardabil

Postal code

Phone

+98 45 3324 8888

Fax

Email

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty